Q.What is the present world scenario of intellectual property rights with respect to life materials? Although, India is second in the world to file patents, still only a few have been commercialized. Explain the reasons behind this less commercialization.

Body Analysis

Global Scenario of IPR for Life Materials

• International Frameworks: Global standards are governed by agreements like TRIPS and the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA), which regulate patenting of biological innovations. Developed economies like the US, EU, and Japan lead in commercializing biotech patents due to mature innovation ecosystems.
• Patent Scope and Ethical Debates: Patents are increasingly granted for genetic engineering and pharmaceuticals, though ethical concerns regarding gene patenting and Genetically Modified Organisms (GMOs) continue to shape global regulatory policies.
• Emerging Markets: While India and China have emerged as major hubs for patent filings, they continue to grapple with challenges related to enforcement, regulatory delays, and commercial translation.

Reasons for Low Commercialization of Patents in India

• Weak Industry-Academia Linkages: There is a significant disconnect between academic research labs and industrial players, preventing laboratory innovations from transitioning into marketable products.
• Funding Deficits: Innovators face immense hurdles in securing venture capital and public funding for the highly expensive phases of product development, clinical trials, and regulatory approvals.
• Regulatory Bottlenecks: Complex and protracted approval processes by bodies like the Drug Controller General of India (DCGI) delay the market entry of biotech products. Additionally, stringent provisions like Section 3(d) of the Indian Patent Act discourage incremental patenting.
• Inadequate Innovation Ecosystem: India lacks a dense network of technology transfer offices, specialized incubators, and IPR support systems that are common in developed nations like Germany or the US.
• Low Commercial Awareness: Many researchers lack the necessary business, legal, and marketing expertise required to navigate the commercialization pipeline.
• Market Viability and High Costs: High development costs coupled with uncertain market demand for niche life-science innovations deter private investment.
• Ethical and Legal Hurdles: Disputes over bioprospecting, benefit-sharing, and genetic resources often lead to prolonged litigation, stalling commercialization.

Way Forward

• Strengthen Industry-Academia Ties: Establish dedicated technology transfer cells in universities to bridge the gap with industries.
• Enhance Financial Support: Provide targeted grants and venture capital funds for early-stage biotech startups.
• Streamline Approvals: Implement single-window clearance mechanisms to expedite regulatory reviews.
• Capacity Building: Educate researchers on patent commercialization strategies and market dynamics.